Neurocrine Biosciences (NBIX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec26

Deutsche Bank Maintains Neurocrine Biosciences Stock Rating and Price Target

10:41

Dec22

Neuroseer Biologics' Valbenazine Phase 3 Clinical Trial for Cerebral Palsy Fails to Meet Endpoints

21:06

Dec9

Neurosecretion Biopharma to Host 2025 R&D Day on December 16

21:01

Dec6

TD Cowen Raises Neurocrine Biosciences Target Price to $200

17:56

Dec3

Russell Investments Reduces Holdings in Neurosign Bioscience

10:51

Dec2

Neurosecretion Biotech's CBO Disposes of Common Stock

22:22

Schedules & Filings

Schedules

Filings

Oct28

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 794.9 M, Net Income 209.5 M, EPS 2.04

Jul30

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 687.5 M, Net Income 107.5 M, EPS 1.06

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 572.6 M, Net Income 7.9 M, EPS 0.0792

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change